BR9907883A - Composição de vacina, processo para eliciar uma resposta imune a um antìgeno de vìrus de herpes simplex, e, composição imunogênica - Google Patents

Composição de vacina, processo para eliciar uma resposta imune a um antìgeno de vìrus de herpes simplex, e, composição imunogênica

Info

Publication number
BR9907883A
BR9907883A BR9907883A BR9907883A BR9907883A BR 9907883 A BR9907883 A BR 9907883A BR 9907883 A BR9907883 A BR 9907883A BR 9907883 A BR9907883 A BR 9907883A BR 9907883 A BR9907883 A BR 9907883A
Authority
BR
Brazil
Prior art keywords
immune response
herpes simplex
simplex virus
elicit
virus antigen
Prior art date
Application number
BR9907883A
Other languages
English (en)
Portuguese (pt)
Inventor
John H Eldridge
Eric M Mishkin
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of BR9907883A publication Critical patent/BR9907883A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5434IL-12
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/245Herpetoviridae, e.g. herpes simplex virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55522Cytokines; Lymphokines; Interferons
    • A61K2039/55527Interleukins
    • A61K2039/55538IL-12
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16611Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
BR9907883A 1998-02-12 1999-02-10 Composição de vacina, processo para eliciar uma resposta imune a um antìgeno de vìrus de herpes simplex, e, composição imunogênica BR9907883A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7450398P 1998-02-12 1998-02-12
PCT/US1999/002923 WO1999040938A2 (en) 1998-02-12 1999-02-10 Vaccines comprising interleukin-12 and herpes simplex viral antigen

Publications (1)

Publication Number Publication Date
BR9907883A true BR9907883A (pt) 2000-11-14

Family

ID=22119907

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9907883A BR9907883A (pt) 1998-02-12 1999-02-10 Composição de vacina, processo para eliciar uma resposta imune a um antìgeno de vìrus de herpes simplex, e, composição imunogênica

Country Status (15)

Country Link
US (1) US6488936B1 (enExample)
EP (1) EP1053017B1 (enExample)
JP (1) JP2002502884A (enExample)
KR (1) KR100622716B1 (enExample)
CN (1) CN1224422C (enExample)
AT (1) ATE275421T1 (enExample)
AU (1) AU764036B2 (enExample)
BR (1) BR9907883A (enExample)
CA (1) CA2320041A1 (enExample)
DE (1) DE69919984T2 (enExample)
DK (1) DK1053017T3 (enExample)
ES (1) ES2226338T3 (enExample)
IL (1) IL137811A (enExample)
PT (1) PT1053017E (enExample)
WO (1) WO1999040938A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20013916A3 (cs) 1999-05-13 2002-06-12 American Cyanamid Company Adjuvantní kombinované prostředky
ATE319833T1 (de) * 1999-12-17 2006-03-15 Wyeth Corp Impfstoffe zur erhöhung der immunantworten gegen herpes simplex virus
US20070025958A1 (en) 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
CA2950109C (en) 2000-10-27 2019-02-19 John W. Hadden Vaccine immunotherapy for immune suppressed patients
HUP0600589A2 (en) * 2000-11-10 2006-11-28 Wyeth Corp Adjuvant combination formulations
US6867000B2 (en) 2000-12-07 2005-03-15 Wyeth Holdings Corporation Method of enhancing immune responses to herpes
JP2004099584A (ja) 2002-05-02 2004-04-02 Keio Gijuku Hsvを用いた抗腫瘍剤
CN1301749C (zh) * 2005-12-09 2007-02-28 复旦大学 抗单纯疱疹病毒-2感染的多表位dna疫苗及其制备方法
US7790203B2 (en) * 2005-12-13 2010-09-07 Lowder Tom R Composition and regimen for the treatment of herpes simplex virus, herpes zoster, and herpes genitalia epidermal herpetic lesions
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US8273361B2 (en) 2006-09-26 2012-09-25 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
CA3017298C (en) 2009-05-15 2021-09-28 Irx Therapeutics, Inc. Compositions comprising primary cell-derived biologics for enhancing immune responses in patients
LT2437753T (lt) 2009-06-05 2016-12-12 Infectious Disease Research Institute Sintetiniai gliukopiranozillipidų adjuvantai ir juos turinčios vakcinų kompozicijos
US8729058B2 (en) * 2009-10-27 2014-05-20 Michael Zasloff Methods and compositions for treating and preventing viral infections
CN103097543A (zh) 2009-12-08 2013-05-08 伊尔克斯治疗有限公司 逆转朗格汉斯细胞免疫抑制的方法
WO2012141984A1 (en) 2011-04-08 2012-10-18 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
LT2850431T (lt) 2012-05-16 2018-06-25 Immune Design Corp. Vakcinos, skirtos hsv-2
KR102039520B1 (ko) 2013-04-18 2019-11-01 이뮨 디자인 코포레이션 암 치료에 이용하기 위한 gla 단일요법
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
CA3023446A1 (en) 2016-05-10 2017-11-16 Hennepin Healthcare Research Institute Cytokine signaling immunomodulators and methods

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022473A1 (en) * 1993-04-01 1994-10-13 University Of Washington Use of interleukin 7 to improve vaccine potency
US5571515A (en) * 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
IL114576A0 (en) * 1994-07-22 1995-11-27 Merck & Co Inc Polynucleotide herpes virus vaccine
GB9422990D0 (en) * 1994-11-15 1995-01-04 Cortecs Ltd Immunogenic compositions
WO1998008947A1 (en) * 1995-12-19 1998-03-05 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Enhancement of dna immunization through the use of cytokines

Also Published As

Publication number Publication date
KR20010040867A (ko) 2001-05-15
EP1053017A2 (en) 2000-11-22
JP2002502884A (ja) 2002-01-29
CA2320041A1 (en) 1999-08-19
WO1999040938A2 (en) 1999-08-19
KR100622716B1 (ko) 2006-09-13
IL137811A0 (en) 2001-10-31
AU2598199A (en) 1999-08-30
ES2226338T3 (es) 2005-03-16
PT1053017E (pt) 2004-12-31
WO1999040938A3 (en) 2000-08-24
IL137811A (en) 2005-12-18
AU764036B2 (en) 2003-08-07
EP1053017B1 (en) 2004-09-08
DK1053017T3 (da) 2004-11-22
US6488936B1 (en) 2002-12-03
CN1299287A (zh) 2001-06-13
DE69919984T2 (de) 2005-11-17
DE69919984D1 (de) 2004-10-14
CN1224422C (zh) 2005-10-26
ATE275421T1 (de) 2004-09-15

Similar Documents

Publication Publication Date Title
BR9907883A (pt) Composição de vacina, processo para eliciar uma resposta imune a um antìgeno de vìrus de herpes simplex, e, composição imunogênica
WO1999040936A3 (en) Pneumococcal and meningococcal vaccines formulated with interleukin-12
AUPR011700A0 (en) Composition comprising immunogenic virus sized particles (VSP)
MX9702336A (es) Composiciones de vacuna.
MX9401225A (es) Composicion de vacuna para prevenir la infeccion con influenza en humanos y metodo para su preparacion.
PT869814E (pt) Estabilizantes para vacinas vivas
PT941315E (pt) Proteinas de stress contendo proteinas de fusao para induzir respostas imunitarias
ATE315405T1 (de) Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
FI953608A7 (fi) Rokoteyhdisteet ja menetelmä immuunireaktion aikaansaamiseksi limakalv ossa järjestelmällisellä rokottamisella
BR9708387A (pt) Processo para vacinação de um mamìfero a um antìgeno selecionado, células patogênica e hospedeira, composição de vacina, ácido nucleico, e, opsonina engenheirada.
PT851927E (pt) Compostos para imunoterapia e diagnostico de tuberculose
EP1032417A4 (en) BACTERIAL VACCINES CONTAINING ATTENUATED AUXOTROPHIC STRAINS OF LISTERIA EXPRESSING HETEROLOGIC ANTIGENS
NO933261L (no) Blanding til forsterkning av immunforsvaret
PT745388E (pt) Composicao de vacinas para mamiferos compreendendo esqualeno ou esqualano fosfolipido e um tensioactivo como adjevante
PT1047446E (pt) Composicao vacinica para o virus herpes simplex e metodos de utilizacao
AU1815899A (en) Method and composition to enhance the efficacy of a vaccine using chemokines
ATE319833T1 (de) Impfstoffe zur erhöhung der immunantworten gegen herpes simplex virus
ES2177535T3 (es) Vacunas contra protozoos intestinales.
BR9912067A (pt) Composição liofilizada, composição de vacina composta e aquosa composta da composição liofilizada, composição de vacina, método de imunização de um vertebrado através de vacinação, método para a preparação de uma composição liofilizada e de uma suspensão coloidal aquosa
GB9818133D0 (en) Vaccine
BR9907885A (pt) Composição de vacina, processo para fazer surgir uma resposta imune a um antìgeno de vìrus sincicial respiratório, e, composição imunogênica
DE60131975D1 (de) Anwendung des herpes simplex virus glykoproteins-d zur unterdrückung von immunantworten
WO2001035993A3 (en) Compositions and methods for stimulating an immune response against infectious agents
ATE350058T1 (de) Sich gegenseitig schützende herpesviruszusammensetzung und verfahren zur deren herstellung und verwendung

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B10A Cessation: cessation confirmed

Free format text: HOMOLOGADA A DESISTENCIA DO PEDIDO, SOLICITADA ATRAVES DA PETICAO NO 20090048590/RJ DE 20.05.2009.